Vericel Shares Outstanding 2006-2021 | VCEL

Vericel shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Vericel Annual Shares Outstanding
(Millions of Shares)
2020 47
2019 44
2018 40
2017 33
2016 23
2015 24
2014 12
2013 3
2012 2
2011 2
2010
2010 1
2009 1
2008 1
2007 1
2006 1
2005 1
Vericel Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 46
2021-03-31 46
2020-12-31 47
2020-09-30 47
2020-06-30 45
2020-03-31 45
2019-12-31 44
2019-09-30 47
2019-06-30 44
2019-03-31 44
2018-12-31 40
2018-09-30 43
2018-06-30 38
2018-03-31 36
2017-12-31 33
2017-09-30 34
2017-06-30 33
2017-03-31 32
2016-12-31 23
2016-09-30 23
2016-06-30 23
2016-03-31 23
2015-12-31 24
2015-09-30 24
2015-06-30 24
2015-03-31 24
2014-12-31 12
2014-09-30 10
2014-06-30 7
2014-03-31 6
2013-12-31 3
2013-09-30 3
2013-06-30 2
2013-03-31 2
2012-12-31 2
2012-09-30 43
2012-06-30 2
2012-03-31 2
2011-12-31 2
2011-09-30 2
2011-06-30 2
2011-03-31 2
2010-12-31
2010-09-30 1
2010-06-30 1
2010-03-31 1
2009-12-31 1
2009-09-30 1
2009-06-30
2009-03-31 1
2008-12-31 1
2008-09-30 1
2008-06-30
2008-03-31 1
2007-12-31 1
2007-09-30 1
2007-06-30
2007-03-31 1
2006-12-31 1
2006-09-30 1
2006-06-30
2006-03-31 1
2005-12-31 1
2005-09-30 1
2005-06-30
2005-03-31 1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.358B $0.124B
Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57